Quantum Leap award applications are due September 30th.

Learn More

News Archive

June 09, 2021

Insilico Medicine Collaborates with the Indiana Biosciences Research Institute

Insilico Medicine , a global leader in deep learning for drug discovery and development, is pleased to announce that it has entered into a research collaboration with the Indiana Biosciences...

June 07, 2021

IBRI IN THE NEWS: BioCrossroads Adds to Board

BioCrossroads has added Adrienne Brown and Alan Palkowitz to its board of directors. Brown serves as vice president of US Diabetes at Eli Lilly and Co. and oversees commercial efforts...

June 01, 2021

BioCrossroads adds Lilly, Indiana Biosciences Research Institute executives to Board of Directors

Indianapolis, Ind. – BioCrossroads announces that Adrienne Brown, vice president of US Diabetes at Eli Lilly and Company, and Alan Palkowitz, PhD, president and CEO of the Indiana Biosciences Research...

May 06, 2021

IBRI Receives Greenovation Award from Kimberly-Clark

In 2020, the IBRI diverted more than 370 pounds of waste from landfills, by participating in the RightCycle Program with Kimberly-Clark Professional....

April 30, 2021

IBRI RESEARCH PUBLISHED: The role of mediobasal hypothalamic PACAP in the control of body weight and metabolism

Abstract Body energy homeostasis results from balancing energy intake and energy expenditure. Central nervous system administration of pituitary adenylate cyclase activating polypeptide (PACAP) dramatically alters metabolic function, but the...

April 05, 2021

IBRI RESEARCH PUBLISHED: Multiplexed Signal Ion Emission Reactive Release Amplification Assay for the Culture-Free Detection of Gram-Negative, Gram-Positive Bacteria and Antimicrobial Resistance Genes

Abstract The global prevalence of antibiotic-resistant bacteria has increased the risk of dangerous infections, requiring rapid diagnosis and treatment. The standard method for diagnosis of bacterial infections remains dependent...

March 29, 2021

IBRI RESEARCH PUBLISHED: Endogenous mitochondrial double-stranded RNA is not an activator of the type I interferon response in human pancreatic beta cells

Abstract Background: Type 1 diabetes (T1D) is an autoimmune disease characterized by the progressive destruction of pancreatic beta cells. Interferon-α (IFNα), an antiviral cytokine, is expressed in the pancreatic...

March 19, 2021

IBRI IN THE NEWS: IBRI's new CEO brings experience from industry, academia

Dr. Alan Palkowitz spent 28 years in industry before becoming an academic research scientist. Those two experiences were perfect preparation for his new role as the leader of an organization...

March 08, 2021

IBRI RESEARCH PUBLISHED: Metabolic roles of G protein-coupled receptor signaling in obesity and type 2 diabetes

Abstract The incidence of obesity and type 2 diabetes (T2D) has been increasing steadily worldwide. It is estimated that by 2045 more than 800 million people will be suffering...

February 19, 2021

IBRI RESEARCH PUBLISHED: Pro-Inflammatory Cytokines Induce Insulin and Glucagon Double Positive Human Islet Cells That Are Resistant to Apoptosis

Abstract The presence of islet cells double positive for insulin and glucagon (Ins + /Glu + ) has been described in the pancreas from both type 2 (T2D) and...

 1 2 3 4 5  ... Last